^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    Itari (linperlisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Heliyon
    Title:

    Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer

    Published date:
    07/20/2023
    Excerpt:
    Patient-derived HR + ABC xenografts were implanted into immune-humanized NSG mice and subsequently treated with YY20394 (PI3Kδ inhibitor) and camrelizumab….The humanized PDX model showed a favorable initial treatment response to camrelizumab combined with YY20394 and manageable toxicity. YY20394 plus camrelizumab showed a strong inhibitory effect on HR + BC in vivo...Our study suggests PI3Kδ inhibitor could the enhance the efficacy of ICIs in HR + BC PDX models by combating immune suppression and provides a feasible approach that may overcome the resistance of ICIs in HR + BC patients.
    DOI:
    10.1016/j.heliyon.2023.e18498